| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/10/2004 | US6689906 Bicyclic amino acids as pharmaceutical agents |
| 02/10/2004 | US6689896 Thyromimetic organic compounds |
| 02/10/2004 | US6689889 Using n-acryloxyphenylaniline neomenthylamide |
| 02/10/2004 | US6689886 Treatment of inflammation and other immune disorders |
| 02/10/2004 | US6689866 Isolated polypeptide comprising specified amino acid sequence; membrane-bound or secreted polypeptide having semaphorin-like activity |
| 02/10/2004 | US6689812 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 02/10/2004 | US6689808 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them |
| 02/10/2004 | US6689807 Activating akt |
| 02/10/2004 | US6689797 Tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 02/10/2004 | US6689794 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/10/2004 | US6689790 Substituted triazolopyridine compounds |
| 02/10/2004 | US6689786 Sulfonylurea, sulfonylthiourea, sulfonylguanidine, sulfonylcyanoguanidine and acylsulfonamide derivatives; antithrombotics |
| 02/10/2004 | US6689784 Controlling cell apoptosis |
| 02/10/2004 | US6689778 2-phenylamino-5-isoxazo-4-yl-pyrimidine derivatives |
| 02/10/2004 | US6689771 Amide derivatives as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase |
| 02/10/2004 | US6689764 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 02/10/2004 | US6689751 Peptide comprising amino acid sequence 15 or 83 with alanine or alpha-aminoisobutyrate substitution |
| 02/10/2004 | US6689741 Biocompatible polymers, process for their preparation and compositions containing them |
| 02/10/2004 | US6689597 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 02/10/2004 | US6689562 Mammalian IAP gene family, primers, probes and detection methods |
| 02/10/2004 | US6689400 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 02/10/2004 | US6689359 Ligands, including antibodies, showing reactivity against endocrine cells |
| 02/10/2004 | US6689337 Vitronectin receptor antagonist pharmaceuticals |
| 02/10/2004 | CA2231026C Novel derivatives of benzenesulfonylamine, process for their preparation and pharmaceutical compositions containing them |
| 02/10/2004 | CA2180301C Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
| 02/10/2004 | CA2164951C Lipoxin compounds |
| 02/10/2004 | CA2108903C Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| 02/08/2004 | CA2433114A1 Method of using metaloporphyrins for treatment of arteriosclerotic lesions |
| 02/05/2004 | WO2004011662A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | WO2004011661A1 Novel physiologically active substances |
| 02/05/2004 | WO2004011470A1 Furoisoquinoline derivative and use thereof |
| 02/05/2004 | WO2004011465A1 Kinase inhibitors |
| 02/05/2004 | WO2004011459A1 Novel physiologically active substance |
| 02/05/2004 | WO2004011444A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011432A1 Organic acid salt of amlodipine |
| 02/05/2004 | WO2004011423A2 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | WO2004011418A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 02/05/2004 | WO2004011416A1 CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST |
| 02/05/2004 | WO2004011410A1 Chemical compounds |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004011028A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | WO2004011018A2 Methods of identifying selective beta-1-adrenergic receptor antagonists |
| 02/05/2004 | WO2004011016A1 Cardiovascular health enhancement with soy fortified orange juice compositions |
| 02/05/2004 | WO2004011010A1 Myocardial perfusion imaging using a2a receptor agonists |
| 02/05/2004 | WO2004011006A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010993A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010991A1 Food improving blood flow |
| 02/05/2004 | WO2004010987A2 Use of s1p receptor agonists in heart diseases |
| 02/05/2004 | WO2004010980A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010959A2 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| 02/05/2004 | WO2004010954A2 Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase |
| 02/05/2004 | WO2004010951A2 Method of treating tumors |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003080181A3 Storage stable eplerenone formulation |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | WO2003064388A3 Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
| 02/05/2004 | WO2003063849A9 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 02/05/2004 | WO2003055911A8 Cystine-knot fold protein |
| 02/05/2004 | WO2003042397A3 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 02/05/2004 | WO2003020947A3 Mid 9002, a human sulfatase family member and uses therefor |
| 02/05/2004 | WO2002100886A8 Pyrrolidin-2-one derivatives as inhibitors of factor xa |
| 02/05/2004 | WO2002041834A8 Atorvastatin hemi-calcium form vii |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040024450 Drug-delivery endovascular stent and method for treating restenosis |
| 02/05/2004 | US20040024218 Novel compounds |
| 02/05/2004 | US20040024215 Such as 4'-trifluoromethyl-biphenyl-2-carboxylic acid(4-(4-(alpha-methyl-benzyl)-piperazin-1-yl)-phenyl)-amide; apoprotein B-100 (apoB-100) and microsomal triglyceride transfer protein (MTP) |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024179 Comprises peptide with heparin and/or lipopolysaccharide binding activity for use as treatment of endotoxic shock and endometriosis, anticoagulant, angiogenesis inhibitor, antiproliferative agent and contraceptive |
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024062 Inhibiting a condition mediated by the alpha v beta 3 or alpha v beta 5 integrin; antitumor, -metastasis, -arthritic agents; angiogenesis, inhibitors; osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration |
| 02/05/2004 | US20040024061 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024034 For modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus |
| 02/05/2004 | US20040024029 Thiazole and oxazole derivatives |
| 02/05/2004 | US20040024002 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 02/05/2004 | US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors |
| 02/05/2004 | US20040023996 Methods and compositions utilizing quinazolinones |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023990 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023989 Pyrazolo(4,3-c)piperidine and pyrazolo(4,3-d)pyrimidine derivatives |
| 02/05/2004 | US20040023988 Novel compounds |
| 02/05/2004 | US20040023986 Treating epilepsy, neuropathic pain, and tissue damage form ischemic events; antihypoxic agents |
| 02/05/2004 | US20040023985 Hydrating 4-(4-fluorophenyl)-2-methyl-6-(5-piperidino pentyloxy) pyrimidine and converting into an acid salt |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023973 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. |
| 02/05/2004 | US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |